Regulation of Class IA PI 3-kinases

C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants

Haiyan Wu, S. Chandra Shekar, Rory J. Flinn, Mirvat El-Sibai, Bijay S. Jaiswal, K. Ilker Sen, Vasantharajan Janakiraman, Somasekar Seshagiri, Gary J. Gerfen, Mark E. Girvin, Jonathan M. Backer

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We previously proposed a model of Class IA PI3K regulation in which p85 inhibition of p110α requires (i) an inhibitory contact between the p85 nSH2 domain and the p110α helical domain, and (ii) a contact between the p85 nSH2 and iSH2 domains that orients the nSH2 so as to inhibit p110α. We proposed that oncogenic truncations of p85 fail to inhibit p110 due to a loss of the iSH2-nSH2 contact. However, we now find that within the context of a minimal regulatory fragment of p85 (the nSH2-iSH2 fragment, termed p85ni), the nSH2 domain rotates much more freely (τc≈12.7 ns) than it could if it were interacting rigidly with the iSH2 domain. These data are not compatible with our previous model. We therefore tested an alternative model in which oncogenic p85 truncations destabilize an interface between the p110α C2 domain (residue N345) and the p85 iSH2 domain (residues D560 and N564). p85ni-D560K/N564K shows reduced inhibition of p110α, similar to the truncated p85ni-572STOP. Conversely, wild-type p85ni poorly inhibits p110αN345K. Strikingly, the p110αN345K mutant is inhibited to the same extent by the wild-type or truncated p85ni, suggesting that mutation of p110α-N345 is not additive with the p85ni-572STOP mutation. Similarly, the D560K/N564K mutation is not additive with the p85ni-572 STOP mutant for downstream signaling or cellular transformation. Thus, our data suggests that mutations at the C2-iSH2 domain contact and truncations of the iSH2 domain, which are found in human tumors, both act by disrupting the C2-iSH2 domain interface.

Original languageEnglish (US)
Pages (from-to)20258-20263
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume106
Issue number48
DOIs
StatePublished - Dec 1 2009

Fingerprint

Phosphatidylinositol 3-Kinases
Mutation
C2 Domains
IA 3
Neoplasms

Keywords

  • Cancer
  • Glioblastoma
  • Phosphoinositide 3-kinase
  • PIK3CA

ASJC Scopus subject areas

  • General

Cite this

Regulation of Class IA PI 3-kinases : C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants. / Wu, Haiyan; Chandra Shekar, S.; Flinn, Rory J.; El-Sibai, Mirvat; Jaiswal, Bijay S.; Sen, K. Ilker; Janakiraman, Vasantharajan; Seshagiri, Somasekar; Gerfen, Gary J.; Girvin, Mark E.; Backer, Jonathan M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 48, 01.12.2009, p. 20258-20263.

Research output: Contribution to journalArticle

Wu, Haiyan ; Chandra Shekar, S. ; Flinn, Rory J. ; El-Sibai, Mirvat ; Jaiswal, Bijay S. ; Sen, K. Ilker ; Janakiraman, Vasantharajan ; Seshagiri, Somasekar ; Gerfen, Gary J. ; Girvin, Mark E. ; Backer, Jonathan M. / Regulation of Class IA PI 3-kinases : C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants. In: Proceedings of the National Academy of Sciences of the United States of America. 2009 ; Vol. 106, No. 48. pp. 20258-20263.
@article{70992748e60040459bb62fa051fa332b,
title = "Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants",
abstract = "We previously proposed a model of Class IA PI3K regulation in which p85 inhibition of p110α requires (i) an inhibitory contact between the p85 nSH2 domain and the p110α helical domain, and (ii) a contact between the p85 nSH2 and iSH2 domains that orients the nSH2 so as to inhibit p110α. We proposed that oncogenic truncations of p85 fail to inhibit p110 due to a loss of the iSH2-nSH2 contact. However, we now find that within the context of a minimal regulatory fragment of p85 (the nSH2-iSH2 fragment, termed p85ni), the nSH2 domain rotates much more freely (τc≈12.7 ns) than it could if it were interacting rigidly with the iSH2 domain. These data are not compatible with our previous model. We therefore tested an alternative model in which oncogenic p85 truncations destabilize an interface between the p110α C2 domain (residue N345) and the p85 iSH2 domain (residues D560 and N564). p85ni-D560K/N564K shows reduced inhibition of p110α, similar to the truncated p85ni-572STOP. Conversely, wild-type p85ni poorly inhibits p110αN345K. Strikingly, the p110αN345K mutant is inhibited to the same extent by the wild-type or truncated p85ni, suggesting that mutation of p110α-N345 is not additive with the p85ni-572STOP mutation. Similarly, the D560K/N564K mutation is not additive with the p85ni-572 STOP mutant for downstream signaling or cellular transformation. Thus, our data suggests that mutations at the C2-iSH2 domain contact and truncations of the iSH2 domain, which are found in human tumors, both act by disrupting the C2-iSH2 domain interface.",
keywords = "Cancer, Glioblastoma, Phosphoinositide 3-kinase, PIK3CA",
author = "Haiyan Wu and {Chandra Shekar}, S. and Flinn, {Rory J.} and Mirvat El-Sibai and Jaiswal, {Bijay S.} and Sen, {K. Ilker} and Vasantharajan Janakiraman and Somasekar Seshagiri and Gerfen, {Gary J.} and Girvin, {Mark E.} and Backer, {Jonathan M.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1073/pnas.0902369106",
language = "English (US)",
volume = "106",
pages = "20258--20263",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "48",

}

TY - JOUR

T1 - Regulation of Class IA PI 3-kinases

T2 - C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants

AU - Wu, Haiyan

AU - Chandra Shekar, S.

AU - Flinn, Rory J.

AU - El-Sibai, Mirvat

AU - Jaiswal, Bijay S.

AU - Sen, K. Ilker

AU - Janakiraman, Vasantharajan

AU - Seshagiri, Somasekar

AU - Gerfen, Gary J.

AU - Girvin, Mark E.

AU - Backer, Jonathan M.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - We previously proposed a model of Class IA PI3K regulation in which p85 inhibition of p110α requires (i) an inhibitory contact between the p85 nSH2 domain and the p110α helical domain, and (ii) a contact between the p85 nSH2 and iSH2 domains that orients the nSH2 so as to inhibit p110α. We proposed that oncogenic truncations of p85 fail to inhibit p110 due to a loss of the iSH2-nSH2 contact. However, we now find that within the context of a minimal regulatory fragment of p85 (the nSH2-iSH2 fragment, termed p85ni), the nSH2 domain rotates much more freely (τc≈12.7 ns) than it could if it were interacting rigidly with the iSH2 domain. These data are not compatible with our previous model. We therefore tested an alternative model in which oncogenic p85 truncations destabilize an interface between the p110α C2 domain (residue N345) and the p85 iSH2 domain (residues D560 and N564). p85ni-D560K/N564K shows reduced inhibition of p110α, similar to the truncated p85ni-572STOP. Conversely, wild-type p85ni poorly inhibits p110αN345K. Strikingly, the p110αN345K mutant is inhibited to the same extent by the wild-type or truncated p85ni, suggesting that mutation of p110α-N345 is not additive with the p85ni-572STOP mutation. Similarly, the D560K/N564K mutation is not additive with the p85ni-572 STOP mutant for downstream signaling or cellular transformation. Thus, our data suggests that mutations at the C2-iSH2 domain contact and truncations of the iSH2 domain, which are found in human tumors, both act by disrupting the C2-iSH2 domain interface.

AB - We previously proposed a model of Class IA PI3K regulation in which p85 inhibition of p110α requires (i) an inhibitory contact between the p85 nSH2 domain and the p110α helical domain, and (ii) a contact between the p85 nSH2 and iSH2 domains that orients the nSH2 so as to inhibit p110α. We proposed that oncogenic truncations of p85 fail to inhibit p110 due to a loss of the iSH2-nSH2 contact. However, we now find that within the context of a minimal regulatory fragment of p85 (the nSH2-iSH2 fragment, termed p85ni), the nSH2 domain rotates much more freely (τc≈12.7 ns) than it could if it were interacting rigidly with the iSH2 domain. These data are not compatible with our previous model. We therefore tested an alternative model in which oncogenic p85 truncations destabilize an interface between the p110α C2 domain (residue N345) and the p85 iSH2 domain (residues D560 and N564). p85ni-D560K/N564K shows reduced inhibition of p110α, similar to the truncated p85ni-572STOP. Conversely, wild-type p85ni poorly inhibits p110αN345K. Strikingly, the p110αN345K mutant is inhibited to the same extent by the wild-type or truncated p85ni, suggesting that mutation of p110α-N345 is not additive with the p85ni-572STOP mutation. Similarly, the D560K/N564K mutation is not additive with the p85ni-572 STOP mutant for downstream signaling or cellular transformation. Thus, our data suggests that mutations at the C2-iSH2 domain contact and truncations of the iSH2 domain, which are found in human tumors, both act by disrupting the C2-iSH2 domain interface.

KW - Cancer

KW - Glioblastoma

KW - Phosphoinositide 3-kinase

KW - PIK3CA

UR - http://www.scopus.com/inward/record.url?scp=73949084778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949084778&partnerID=8YFLogxK

U2 - 10.1073/pnas.0902369106

DO - 10.1073/pnas.0902369106

M3 - Article

VL - 106

SP - 20258

EP - 20263

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 48

ER -